Efficacy of a point-of-care test based on deamidated gliadin peptides for the detection of celiac disease in pediatric patients

Objective: The objective of the study was to assess the effectiveness of a point-of-care test (POCT) based on deamidated gliadin peptides (DGP) compared to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria diagnosis in the early detection of celiac disease (CD) in pediatric patients. Methods: One hundred children (≤ 18 years) with suspected CD were selected, including siblings of celiac children that underwent gastroscopy for other gastrointestinal conditions. Patients with severe disease, following a gluten-free diet (GFD), with gastrointestinal bleeding, coagulopathy and infections in the last month were excluded. All children were evaluated with a POCT that detects immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies to DGP and total IgA. The POCT results were compared to CD diagnosis according to current ESPGHAN criteria. This involved the detection of IgA tissue transglutaminase (tTG) antibodies, the results of an intestinal biopsy and genetic testing. Results: The prevalence of CD found in the present study was 48% (95% confidence interval in parenthesis 37.9-58.2%). The results of the POCT were concordant with the CD diagnosis made according to ESPGHAN criteria: 95.8% (85.7-99.4%) sensitivity, 98.1% (89.7-99.7%) specificity, 97.9% (88.7-99.6%) positive predictive value and 96.2% (87.0-99.4%) negative predictive value. Positive and negative likelihood ratios were 49.8 (7.2-347.5) and 0.04 (0.01-0.17), respectively. The POCT showed a 100% diagnostic accuracy in children younger than ten years of age. In total, three discordant results were found. Conclusion: Due to the high diagnostic accuracy in the pediatric population, the POCT can be considered as an effective tool for the early diagnosis of CD, especially in patients younger than ten years of age (AU)

No disponible

Efficacy of a point-of-care test based on deamidated gliadin peptides for the detection of celiac disease in pediatric patients.

OBJECTIVE: The objective of the study was to assess the effectiveness of a point-of-care test (POCT) based on deamidated gliadin peptides (DGP) compared to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria diagnosis in the early detection of celiac disease (CD) in pediatric patients. METHODS: One hundred children (≤ 18 years) with suspected CD were selected, including siblings of celiac children that underwent gastroscopy for other gastrointestinal conditions. Patients with severe disease, following a gluten-free diet (GFD), with gastrointestinal bleeding, coagulopathy and infections in the last month were excluded. All children were evaluated with a POCT that detects immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies to DGP and total IgA. The POCT results were compared to CD diagnosis according to current ESPGHAN criteria. This involved the detection of IgA tissue transglutaminase (tTG) antibodies, the results of an intestinal biopsy and genetic testing. RESULTS: The prevalence of CD found in the present study was 48% (95% confidence interval in parenthesis 37.9-58.2%). The results of the POCT were concordant with the CD diagnosis made according to ESPGHAN criteria: 95.8% (85.7-99.4%) sensitivity, 98.1% (89.7-99.7%) specificity, 97.9% (88.7-99.6%) positive predictive value and 96.2% (87.0-99.4%) negative predictive value. Positive and negative likelihood ratios were 49.8 (7.2-347.5) and 0.04 (0.01-0.17), respectively. The POCT showed a 100% diagnostic accuracy in children younger than ten years of age. In total, three discordant results were found. CONCLUSION: Due to the high diagnostic accuracy in the pediatric population, the POCT can be considered as an effective tool for the early diagnosis of CD, especially in patients younger than ten years of age.

Reference values for leptin, cortisol, insulin and glucose, among European adolescents and their association with adiposity: the HELENA study.

BACKGROUND AND OBJECTIVE: Adequate concentrations of leptin, cortisol, and insulin are important for a suitable metabolism and development during adolescence. These hormones jointly with glucose play a major role in fat metabolism and development of childhood obesity. Our main objective was to quantify biomarkers as leptin, cortisol, insulin and glucose status in European adolescents to contribute to establish reference ranges. METHODS: A representative sample of 927 adolescents (45% males, 14.9±1.2 years for the overall population) from ten European cities of the HELENA study was used to obtain fasting blood samples for these biomarkers. The percentile distributions were computed by sex and age and percentiles were associated with BMI classification. RESULTS: Serum leptin concentration in adolescents varied significantly according to BMI, sex and age (all p < 0.001). Cortisol presented a tendency to increase with age, both for females and males, while insulin and glucose were stable with age. Leptin and insulin were highest in obese adolescents (p < 0.001), whilst cortisol and glucose did not vary with BMI. Percentiles 5, 25, 50, 75 and 95, for hormones values were, respectively: 1.27, 4.06, 11.54, 26.70 and 65.33 ng/ml for leptin; 5.00, 8.11, 11.14, 15.00 and 24.51 µg/dl for cortisol and 3.65, 6.15, 8.52, 11.90 and 20.53 µlU/ml for insulin. CONCLUSIONS: In adolescents, leptin, cortisol, insulin and glucose concentrations are differently affected by age, sex and BMI. Establishment of reference ranges (percentiles) of these biomarkers would be of great interest when pediatricians have to assess the trend of an adolescent to develop obesity years after.

Objetivo: Concentraciones adecuadas de leptina, cortisol e insulina son importantes para un metabolismo normal durante la adolescencia, puesto que valores alterados de estas hormonas, junto con la glucosa, se asocian con el desarrollo de la obesidad infantil. Nuestro principal objetivo fue cuantificar estos marcadores en adolescentes europeos con el fin de establecer rangos de referencia. Métodos: Muestras de sangre procedentes de 927 adolescentes en ayunas (14,9 ± 1,2 años, 45% varones, estudio HELENA), fueron analizadas para cuantificar la leptina, cortisol, insulina y glucosa. Las distribuciones de percentiles se determinaron teniendo en cuenta el sexo y la edad. También se estudió la asociación entre percentiles y la clasificación del IMC. Resultados: La concentración de leptina en suero variaba significativamente con el IMC, el sexo y la edad (todos p.

Reference values for leptin, cortisol, insulin and glucose, among European adolescents and their association with adiposity: The HELENA Study / Valores de referencia para leptina, cortisol, insulina y glucosa entre los adolescentes europeos y su asociación con adiposidad: estudio HELENA

Background and Objective: Adequate concentrations of leptin, cortisol, and insulin are important for a suitable metabolism and development during adolescence. These hormones jointly with glucose play a major role in fat metabolism and development of childhood obesity. Our main objective was to quantify biomarkers as leptin, cortisol, insulin and glucose status in European adolescents to contribute to establish reference ranges. Methods: A representative sample of 927 adolescents (45% males, 14.9±1.2 years for the overall population) from ten European cities of the HELENA study was used to obtain fasting blood samples for these biomarkers. The percentile distributions were computed by sex and age and percentiles were associated with BMI classification. Results: Serum leptin concentration in adolescents varied significantly according to BMI, sex and age (all p<0.001). Cortisol presented a tendency to increase with age, both for females and males, while insulin and gluco- se were stable with age. Leptin and insulin were highest in obese adolescents (p<0.001), whilst cortisol and glucose did not vary with BMI. Percentiles 5, 25, 50, 75 and 95, for hormones values were, respectively: 1.27, 4.06, 11.54, 26.70 and 65.33 ng/ml for leptin; 5.00, 8.11, 11.14, 15.00 and 24.51 µg/dl for cortisol and 3.65, 6.15, 8.52, 11.90 and 20.53 µlU/ml for insulin. Conclusions: In adolescents, leptin, cortisol, insulin and glucose concentrations are differently affected by age, sex and BMI. Establishment of reference ranges (percentiles) of these biomarkers would be of great interest when pediatricians have to assess the trend of an adolescent to develop obesity years after (AU)

Objetivo: Concentraciones adecuadas de leptina, corti- sol e insulina son importantes para un metabolismo normal durante la adolescencia, puesto que valores alterados de estas hormonas, junto con la glucosa, se asocian con el desarrollo de la obesidad infantil. Nuestro principal objetivo fue cuantificar estos marcadores en adolescentes europeos con el fin de establecer rangos de referencia. Métodos: Muestras de sangre procedentes de 927 adolescentes en ayunas (14,9 ± 1,2 años, 45% varones, estudio HELENA), fueron analizadas para cuantificar la leptina, cortisol, insulina y glucosa. Las distribuciones de percentiles se determinaron teniendo en cuenta el sexo y la edad. También se estudió la asociación entre percentiles y la clasificación del IMC. Resultados: La concentración de leptina en suero variaba significativamente con el IMC, el sexo y la edad (todos p<0,001). El cortisol presentó una tendencia a aumentar con la edad, tanto para varones como mujeres, mientras que la insulina y la glucosa eran estables con la edad. La leptina y la insulina fueron más altas en los adolescentesobesos (p <0,001), mientras que el cortisol y glucosa no variaron con el IMC. Los percentiles 5, 25, 50, 75 y 95, para los valores de hormonas fueron, respectivamente: 1.27, 4.06, 11.54, 26.70 y 65.33 ng/ml para la lepti- na; 5.00, 8.11, 11.14, 15.00 y 24.51 µg/dl para el cortisol y 3.65, 6.15, 8.52, 11.90 y 20.53 µlU/ml de insulina. Conclusiones: En los adolescentes, las concentraciones de referencia de leptina, cortisol, insulina y glucosa se ven afectados de manera diferente según la edad, el sexo y el IMC (AU)

Adequate hydration status promotes a lower concentration of proinflammatory cytikines in healthy adults / Una adecuada hidratación promueve una menor concentración de citoquinas proinflamatorias en adultos sanos

Background: Good hydration status (HS) is necessary for an adequate homeostasis of the organism. Cytokines are secreted mainly by inflammatory leukocytes and act as intercellular mediators. Objetive: Assessing pro and anti-inflammatory cytokines concentration in serum and in the aqueous phase of stools (APhS) from healthy adults in function of their HS. Methods: HS data were obtained from 86 healthy adults of 45-65 years old and BMI ≥18.5-<40 kg/m2. HS was measured by bioelectrical impedance (BIA) with a standardized protocol. Cytokines serum concentrations were determined by multiple ELISAs. Stools were recollected by the participants, frozen, and carefully transported to the laboratory where they were stored at -80°C until their determination. Stools were ultra-centrifuged and cytokines were measured in APhS with an ultra-sensible cytokines array. All samples were analyzed in duplicate. Results: Mean age was 51.2 ± 4.9 years old and BMI was 28.2 ± 4.7 kg/m2. The average intake of water from foods and beverages was not adequate enough (1,411.6 ± 427.4 ml/day; 81% consumed less than two-thirds of the recommended intake) however only 89.5% showed an adequate HS and only 10.5% showed clearly dehydration measured by BIA. Volunteers who had good HS had lower values of IFN(2.7 ± 2.4 vs 6.4 ± 4.3 pg/ml; p < 0.05) and IL6 serum (5.5 ± 13.3 vs 6.4 ± 16.3 pg/ml; p < 0.01) than those who had a dehydration status. IL1 from AphS showed lower values in adults with good hydration than those dehydrated (648.3 ± 615 vs 1,194 ± 561.2 pg/ml; p < 0.05). Conclusions: Adults with an appropriate HS have a minor concentration of pro-inflammatory cytokines in serum and in APhS than adults who showed a dehydration status. More studies are needed in order to corroborate these results (AU)

Introducción: Un adecuado estado de hidratación (EH) es necesario para mantener la homesostasis del organismo. Las citoquinas son mediadores intercelulares que son secretadas principalmente por leucocitos. Objetivo: Valorar la concentración de citoquinas pro y antiinflamatorias en suero y la fase acuosa de las heces (FAH) de adultos sanos en función de su EH. Métodos: Se obtuvo información sobre el EH de 86 adultos sanos de 45-65 años y un IMC de 18,5-<40 kg/m2. El EH fue medido por Impedancia Bioeléctrica (BIA) siguiendo el protocolo estándar. La concentración de citoquinas en suero fue determinada por múltiples ELISAs. Las heces fueron recolectadas por los participantes, congeladas y transportadas al laboratorio donde fueron almacenadas a -80°C hasta su determinación. Posteriormente las heces fueron ultracentrifugadas y las citoquinas fueron medidas en la FAH con un array ultrasensible. Resultados: La edad media fue de 51,2 ± 4,9 años y el IMC fue de 28,2 ± 4,7 kg/m2. El consumo medio de agua proveniente de los alimentos y las bebidas realizado por los participantes no fué suficiente (1.411,6 ± 427,4 ml/día; el 81% consumió menos de dos tercios de la ingesta recomendada), sin embargo, el 89,5% presentó un adecuado EH y solo el 10,5% estuvo en rango de deshidratación. Los participantes con un adecuado EH tuvieron valores de IFN(2,7 ± 2,4 vs 6,4 ± 4,3 pg/ml; p < 0,05) e IL6 séricos (5,5 ± 13,3 vs 6,4 ± 16,3 pg/ml; p < 0,01) inferiores a las personas deshidratadas. La IL1 medida en la FAH mostró una concentración más baja en personas bien hidratadas que en aquellas deshidratadas (648,3 ± 615 vs 1194,0 ± 561,2 pg/ml; p < 0,05). Conclusiones: Los adultos de nuestro estudio con un adecuado EH presentan una concentración inferior de citoquinas proinflamatorias en suero y en la FAH que aquellos que estaban deshidratados. Se necesitan más estudios que confirmen estos resultados (AU)

Effects of milk supplementation with conjugated linoleic acidon weight control and body composition in healthy overweight people / Efecto de una suplementación láctea con ácido linoleico conjugado sobre el control de peso y la composición corporal de personas sanas con sobrepeso

Introduction: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. Objetive: The aim of the study was to examine the effects and safety of 3 g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. Methods: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ≥ 27 -<30 kg/m2 who consumed 200 ml/day of skimmed milk with 3g of CLAs or 3g olive oil (placebo). Anthropometric, biochemical and dual x-ray absorptiometry (DXA) tests were measured. Diet and physical activity were assessed. Results: Subjects maintained their habitual dietary and exercise patterns over the study. Only CLA group showed a significant decrease in weight (74.43 ± 10.45 vs 73.54 ± 11.66 kg, p = 0.029) and waist circumference (91.45 ± 10.33 vs 90.65 ± 9.84 cm, p = 0.012) between baseline and end of the study. BMI and waist height ratio decreased (28.44 ± 1.08 vs 27.81 ± 1.43 kg/m2, p = 0.030 and 0.57 ± 0.05 vs 0.56 ± 0.04 p = 0.013 respectively) in CLA group at the end. CLA group experienced a reduction in total fat mass after 24 weeks (38.62 ± 5.02 vs 36.65 ± 5.64%, p = 0.035). No decrease was observed in Control group. HOMA index had no changes. Conclusions: The consumption of skimmed milk enriched with 3g of a 1:1 mixture of c9-t11 and t10-c12 for 24 weeks led to a decrease in body weight and total fat mass in healthy, overweight subjects who maintained habitual diets and exercise patterns. No adverse effects were observed. Registered under ClinicalTrials.gov Identifier No. NCT01503047 (AU)

Introducción: Los ácidos linoleicos conjugados (ALC) han mostrado unos efectos beneficiosos en el tratamiento del control de peso; sin embargo, esta relación no está clara. Objetivo: El propósito de este estudio fue examinar los efectos y la seguridad de 3 g de una mezcla 1:1 de c9-t11 y t10-c12 sobre el control de peso y la composición corporal en individuos sanos con sobrepeso. Métodos: Se realizó un estudio clínico prospectivo, de grupos paralelos, de distribución aleatoria, a doble ciego y con control placebo, de 24 semanas de duración, en 38 voluntarios (29 mujeres, 9 hombres) con edades de 30-55 años y un IMC ≥ 27 -< 30 kg/m2 que consumieron 200 ml/día de leche desnatada con 3 g de ALC o 3 g de aceite de oliva (placebo). Se midieron datos de antropometría, bioquímica y absorciometría dual de rayos X (DXA). Se evaluaron la dieta y la actividad física. Resultados: Los sujetos mantuvieron sus patrones habituales de dieta y ejercicio a lo largo del estudio. Sólo el grupo de ALC mostró una reducción significativa del peso (74,43 ± 10,45 vs 73,54 ± 11,66 kg, p = 0,029) y de la circunferencia de la cintura (91,45 ± 10,33 vs 90,65 ± 9,84 cm, p = 0,012) entre el periodo basal y el final del estudio. El IMC y el cociente cintura/talla disminuyeron (28,44 ± 1,08 vs 27,81 ± 1,43 kg/m2, p = 0,030 y 0,57 ± 0,05 vs 0,56 ± 0,04 p = 0,013, respectivamente) en el grupo ALC al final del estudio. El grupo ALC experimentó una reducción de la masa grasa total tras 24 semanas (38,62 ± 5,02 vs 36,65 ± 5,64 %, p = 0,035). No se observó reducción en el grupo control. El índice HOMA no experimentó cambios. Conclusiones: El consumo de leche desnatada enriquecida con 3 g de una mezcla 1:1 de c9-t11 y t10-c12 durante 24 semanas produjo un descenso del peso corporal y la masa grasa total en sujetos sanos con sobrepeso que mantuvieron sus patrones habituales de dieta y ejercicio físico. No se observaron efectos adversos. Registrado con el identificador núm. NCT01503047 en ClinicalTrials.gov (AU)

[Predictor variables for low adherence to a lifestyle modification program of overweight treatment in primary health care]. / Variables predictoras de baja adherencia a un programa de modificación de estilos de vida para el tratamiento del exceso de peso en atención primaria.

OBJECTIVES: To identify predictive variables of low adherence to a pilot Lifestyle Modification Program (LMP) for overweight and obesity treatment in primary health care (PC ). MATERIAL AND METHODS: Sixty subjects with BMI > 27 kg/m(2) were recruited. Health professionals directed the program in a group structure and biweekly, based on nutrition education with individualized dietary guidelines, promotion of physical activity and motivational support. A validated questionnaire on lifestyle habits for overweight and obesity subjects was used to identify variables related with program adherence and anthropometric variables were measured before and 6 months after intervention. Low adherence was considered when patients attended to less than 80% of visits. RESULTS: Twenty-seven subjects (45%) presented high adherence to the program. The variables associated to low adherence were related to baseline with IMC ≥ 35 kg/m(2) (p < 0.05); ex smoker period ≤ 4 months (p < 0.01); high caloric diet (p < 0.01) and scarce physical activity (p < 0.05). At 6 months the subjects who finalized the program presented a significant decrease of weight (86.0 ± 15.6 vs 79.2 ± 13.4 kg; p < 0,001); fat mass percentage (41,6 ± 4,6 vs 38.8 ± 5,4%; p < 0.001), blood glucose (108 ± 45.48 vs 94.38 ± 11.97 mg/dl; p < 0.01). It also improved caloric diet profile, above all decreasing the percentage of fat (39.6 ± 4.8 vs 35.5 ± 5.6%; p < 0.01). CONCLUSION: Have recently left smoking, obesity degree two or higher, a high caloric diet and scarce physical activity were basal variables identified as predictive of a low adhesion to a LMP for the treatment of overweight and obesity in primary health care. We do not consider this pilot experience as satisfactory and other new strategies are under development.

Objetivos: Identificar variables predictoras de baja adherencia a un programa piloto de Modificación de Estilos de Vida (MEV) para el tratamiento del exceso de peso en Atención Primaria (AP). Material y métodos: Se reclutaron 60 sujetos con IMC > 27 kg/m2. Profesionales sanitarios dirigieron el programa, en formato grupal y con una periodicidad quincenal, basado en educación nutricional, pautas dietéticas individualizadas, promoción de actividad física y apoyo motivacional. Para identificar las variables relacionadas con la adherencia al programa se utilizó un cuestionario validado sobre Hábitos de Vida de personas con Sobrepeso y Obesidad y se midieron variables antropométricas al inicio y a los seis meses del tratamiento. Una baja adherencia al programa fue considerada cuando los sujetos del estudio acudían a menos del 80% de las visitas quincenales. Resultados: Se adhirieron al programa 27 sujetos (45%). Las variables asociadas a baja adherencia estuvieron relacionadas al inicio del estudio con IMC ≥?35 kg/m2 (p < 0,05); período de exfumador =?4 meses (p < 0,01); mayor contenido calórico de la dieta (p < 0,01) y menor práctica de ejercicio físico (p < 0,05). A los 6 meses los sujetos que finalizaron el programa presentaron una disminución significativa de: peso (86,0 ± 15,6 vs 79,2 ± 13,4 kg; p < 0,001);% de masa grasa (41,6 ± 4,6 vs 38,8 ± 5,4%; p < 0,001) y glucemia (108 ± 45,48 vs 94,38 ± 11,97 mg/dl; p < 0,01). Además mejoró el perfil calórico de su dieta, disminuyendo sobretodo el porcentaje de grasa sobre el valor calórico total (39,6 ± 4,8 vs. 35,5 ± 5,6%; p < 0,01). Conclusión: Haber dejado de fumar recientemente, padecer obesidad de grado dos o superior, el alto contenido calórico de la dieta y la menor práctica de ejercicio físico fueron las variables basales identificadas como predictoras de una baja adherencia a un programa de MEV para el tratamiento de sobrepeso y obesidad en AP. Esta experiencia piloto una vez evaluada no la consideramos satisfactoria y otras nuevas estrategias están en fase de desarrollo.

Variables predictoras de baja adherencia a un programa de modificación de estilos de vida para el tratamiento del exceso de peso en atención primaria / Predictor variables for low adherence to a lifestyle modification program of overweight treatment in primary health care

Objetivos: Identificar variables predictoras de baja adherencia a un programa piloto de Modificación de Estilos de Vida (MEV) para el tratamiento del exceso de peso en Atención Primaria (AP). Material y métodos: Se reclutaron 60 sujetos con IMC > 27 kg/m2. Profesionales sanitarios dirigieron el programa, en formato grupal y con una periodicidad quincenal, basado en educación nutricional, pautas dietéticas individualizadas, promoción de actividad física y apoyo motivacional. Para identificar las variables relacionadas con la adherencia al programa se utilizó un cuestionario validado sobre Hábitos de Vida de personas con Sobrepeso y Obesidad y se midieron variables antropométricas al inicio y a los seis meses del tratamiento. Una baja adherencia al programa fue considerada cuando los sujetos del estudio acudían a menos del 80% de las visitas quincenales. Resultados: Se adhirieron al programa 27 sujetos (45%). Las variables asociadas a baja adherencia estuvieron relacionadas al inicio del estudio con IMC ≥ 35 kg/m2 (p < 0,05); período de exfumador ≤ 4 meses (p < 0,01); mayor contenido calórico de la dieta (p < 0,01) y menor práctica de ejercicio físico (p < 0,05). A los 6 meses los sujetos que finalizaron el programa presentaron una disminución significativa de: peso (86,0 ± 15,6 vs 79,2 ± 13,4 kg; p < 0,001); % de masa grasa (41,6 ± 4,6 vs 38,8 ± 5,4%; p < 0,001) y glucemia (108 ± 45,48 vs 94,38 ± 11,97 mg/dl; p < 0,01). Además mejoró el perfil calórico de su dieta, disminuyendo sobretodo el porcentaje de grasa sobre el valor calórico total (39,6 ± 4,8 vs. 35,5 ± 5,6%; p < 0,01). Conclusión: Haber dejado de fumar recientemente, padecer obesidad de grado dos o superior, el alto contenido calórico de la dieta y la menor práctica de ejercicio físico fueron las variables basales identificadas como predictoras de una baja adherencia a un programa de MEV para el tratamiento de sobrepeso y obesidad en AP. Esta experiencia piloto una vez evaluada no la consideramos satisfactoria y otras nuevas estrategias están en fase de desarrollo (AU)

Objectives: To identify predictive variables of low adherence to a pilot Lifestyle Modification Program (LMP) for overweight and obesity treatment in primary health care (PC). Material and methods: Sixty subjects with BMI > 27 kg/m2 were recruited. Health professionals directed the program in a group structure and biweekly, based on nutrition education with individualized dietary guidelines, promotion of physical activity and motivational support. A validated questionnaire on lifestyle habits for overweight and obesity subjects was used to identify variables related with program adherence and anthropometric variables were measured before and 6 months after intervention. Low adherence was considered when patients attended to less than 80% of visits. Results: Twenty-seven subjects (45%) presented high adherence to the program. The variables associated to low adherence were related to baseline with IMC ≥ 35 kg/m2 (p < 0.05); ex smoker period ≤ 4 months (p < 0.01); high caloric diet (p < 0.01) and scarce physical activity (p < 0.05). At 6 months the subjects who finalized the program presented a significant decrease of weight (86.0 ± 15.6 vs 79.2 ± 13.4 kg; p < 0,001); fat mass percentage (41,6 ± 4,6 vs 38.8 ± 5,4%; p < 0.001), blood glucose (108 ± 45.48 vs 94.38 ± 11.97 mg/dl; p < 0.01). It also improved caloric diet profile, above all decreasing the percentage of fat (39.6 ± 4.8 vs 35.5 ± 5.6%; p < 0.01). Conclusion: Have recently left smoking, obesity degree two or higher, a high caloric diet and scarce physical activity were basal variables identified as predictive of a low adhesion to a LMP for the treatment of overweight and obesity in primary health care. We do not consider this pilot experience as satisfactory and other new strategies are under development (AU)

Effects of milk supplementation with conjugated linoleic acid on weight control and body composition in healthy overweight people.

INTRODUCTION: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. OBJETIVE: The aim of the study was to examine the effects and safety of 3g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. METHODS: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ≥27-<30 kg/m2 who consumed 200 ml/day of skimmed milk with 3g of CLAs or 3g olive oil (placebo). Anthropometric, biochemical and dual x-ray absorptiometry (DXA) tests were measured. Diet and physical activity were assessed. RESULTS: Subjects maintained their habitual dietary and exercise patterns over the study. Only CLA group showed a significant decrease in weight (74.43 ± 10.45 vs 73.54 ± 11.66 kg, p = 0.029) and waist circumference (91.45 ± 10.33 vs 90.65 ± 9.84 cm, p = 0.012) between baseline and end of the study. BMI and waist height ratio decreased (28.44 ± 1.08 vs 27.81 ± 1.43 kg/m2, p = 0.030 and 0.57 ± 0.05 vs 0.56 ± 0.04 p = 0.013 respectively) in CLA group at the end. CLA group experienced a reduction in total fat mass after 24 weeks (38.62 ± 5.02 vs 36.65 ± 5.64%, p = 0.035). No decrease was observed in Control group. HOMA index had no changes. CONCLUSIONS: The consumption of skimmed milk enriched with 3g of a 1:1 mixture of c9-t11 and t10-c12 for 24 weeks led to a decrease in body weight and total fat mass in healthy, overweight subjects who maintained habitual diets and exercise patterns. No adverse effects were observed. Registered under ClinicalTrials.gov Identifier No. NCT01503047.

INTRODUCTION: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. OBJETIVE: The aim of the study was to examine the effects and safety of 3g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. METHODS: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ¡Ý27-